Klaviyo, Inc. has filed an amended Form 144 to update the details regarding the sale of shares by its director, Roxanne Oulman. This change is significant as it highlights the company's ongoing activity in the prepackaged software sector, which could impact investor perceptions and market dynamics.
Background
Klaviyo, Inc. operates in the prepackaged software industry, classified under SIC code 7372. The company is publicly traded on the New York Stock Exchange under the ticker symbol KVYO. As a large accelerated filer, Klaviyo has been active in the market, with recent filings indicating various transactions and updates.
What the Filing Says
The amended filing states, "This form 144 amends and supersedes the form 144 filed on 11/06/2026. Lot in the securities to be sold section was updated." This indicates a revision in the number of shares Oulman intends to sell, which has been adjusted to 13,989 shares.
Impact
This update may affect Klaviyo's shareholders and potential investors, as it reflects the director's actions regarding her holdings. The sale, valued at approximately $284,825, may influence how the market perceives the company's stability and growth potential.
What's Next
The filing does not say what happens next.
Details of the Securities
The shares being sold by Roxanne Oulman are classified as Series A shares. The amended filing indicates that Oulman acquired a total of 8,169 shares on June 10, 2025, and an additional 5,820 shares on June 9, 2026, both through restricted stock vesting as part of her compensation.
Brokerage Information
The sale will be facilitated by Fidelity Brokerage Services LLC, located at 900 Salem Street, Smithfield, RI. This brokerage will handle the transaction on behalf of Oulman.
Outstanding Shares
As of the filing date, Klaviyo has a total of 130,150,680 shares outstanding. This figure is essential for understanding the scale of Oulman's sale relative to the company's overall equity structure.
Previous Transactions
The filing notes that there is nothing to report regarding securities sold by Oulman in the past three months, indicating that this sale is a significant event in her recent trading history.
Read Next
Barclays PLC Reports 4.81% Stake in Crown Reserve Acquisition
Barclays PLC Updates Stake in Cartesian Therapeutics, Inc.
Barclays PLC Increases Stake in Penumbra Inc to 4.82%
Barclays PLC Updates Stake in Mercer International Inc.
Barclays PLC Increases Stake in JELD-WEN to 6.86%
Barclays PLC Discloses 2.11% Stake in Calisa Acquisition Corp










